Clinical Trial

Genotype/Phenotype Correlation of MORC2 Mutations

Study acronym: PhenoMORC2
Recruiting
View on ClinicalTrials.gov →
Summary
The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy. Different mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN. MORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-17; most recent amendment 2026-06-17.
Status change: Not Yet Recruiting → Recruiting 2025-07-03
Trial Details
NCT Number NCT07038239
Lead Sponsor Hospices Civils de Lyon
Conditions Charcot Marie Tooth Disease, DIFGAN, Developmental Delay (Disorder), Impaired Growth, Dysmorphic Facies and Axonal Neuropathy
Enrollment 45 participants
Start Date 2026-06-16
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-18